Lucie Valero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lucie Valero has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Audrey Chissey
Université Paris Cité, Inserm, 3PHM, F-75006 Paris, France
1 shared publication - Caroline Roques
Université Paris Cité, CNRS, INSERM, UTCBS
1 shared publication - Danielle Campiol Arruda
Laboratoire de Biologie Tissulaire et d’Ingénierie Thérapeutique, Institut de Biologie et Chimie des Protéines, UMR 5305, CNRS/Université Claude Bernard Lyon 1, 7 Passage du Vercors, CEDEX 07, 69367 Lyon, France
1 shared publication - Hélène Dhotel
Université de Paris, UTCBS (Chemical and Biological Technologies for Health Unit), CNRS, INSERM, 75006 Paris, France
1 shared publication - Jeanne Leblond Chain
ARNA - Acides nucléiques: Régulations naturelles et artificielles
1 shared publication - Jenifer Espinoza Romero
Chimie ParisTech, PSL Research University, University de Technologies Chimiques et Biologiques pour la Santé (UTCBS), F-75005 Paris, France
1 shared publication
Latest Publications
- Open Access
Liposomes as Gene Delivery Vectors for Human Placental Cells
Nanomedicine as a therapeutic approach for pregnancy-related diseases could offer improved treatments for the mother while avoiding side effects for the fetus. In this study, we evaluated the potential of liposomes as carriers for small interfering RNAs to placental cells. Three neutral formulations carrying rhodamine-labelled siRNAs were evaluated on an in vitro model, i.e., human primary villous cytotrophoblasts. siRNA internalization rate from lipoplexes were compared to the one in the presence of the lipofectamine reagent and assessed by confocal microscopy. Results showed cellular internalization of nucleic acid with all three formulations, based on two cationic lipids, either DMAPAP or CSL-3. Moreover, incubation with DMAPAP+AA provided a rate of labelled cells as high as with lipofectamine (53 ± 15% and 44 ± 12%, respectively) while being more biocompatible. The proportion of cells which internalized siRNA were similar when using DMAPAP/DDSTU (16 ± 5%) and CSL-3 (22 ± 5%). This work highlights that liposomes could be a promising approach for gene therapy dedicated to pregnant patients.
Open AccessLiposomes as Gene Delivery Vectors for Human Placental Cells
Nanomedicine as a therapeutic approach for pregnancy-related diseases could offer improved treatments for the mother while avoiding side effects for the fetus. In this study, we evaluated the potential of liposomes as carriers for small interfering RNAs to placental cells. Three neutral formulations carrying rhodamine-labelled siRNAs were evaluated on an in vitro model, i.e., human primary villous cytotrophoblasts. siRNA internalization rate from lipoplexes were compared to the one in the presence of the lipofectamine reagent and assessed by confocal microscopy. Results showed cellular internalization of nucleic acid with all three formulations, based on two cationic lipids, either DMAPAP or CSL-3. Moreover, incubation with DMAPAP+AA provided a rate of labelled cells as high as with lipofectamine (53 ± 15% and 44 ± 12%, respectively) while being more biocompatible. The proportion of cells which internalized siRNA were similar when using DMAPAP/DDSTU (16 ± 5%) and CSL-3 (22 ± 5%). This work highlights that liposomes could be a promising approach for gene therapy dedicated to pregnant patients.